Program Schedule

Clinical Response of Tedizolid Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure: Pooled Analysis of 2 Phase 3 Double-Blind Trials

Session: Poster Abstract Session: Antimicrobial Resistance: Novel Agents and Approaches to Gram-positive Infections
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
  • 150100334-04 Efficacy by Severity Measures Poster L4_100614_FINAL.pdf (603.3 kB)
  • Background: There is no consensus on defining disease severity in acute bacterial skin and skin structure infections (ABSSSI) trials. In two ABSSSI, noninferiority Phase 3 trials (ESTABLISH-1 and ESTABLISH-2), 6 days of tedizolid, a novel oxazolidinone antibacterial, demonstrated noninferior efficacy to 10 days of linezolid.  In this prespecified subgroup analysis, the effect of different measures of disease severity at baseline (lesion size, fever, increased white blood cell count, System Inflammatory Response Syndrome [SIRS], lymphadenopathy, and presence of immature neutrophils [bands]) on clinical response was investigated.

    Methods: Eligible patients were randomized 1:1 to receive 200 mg tedizolid once daily for 6 days or 600 mg linezolid twice daily for 10 days. ESTABLISH-1 patients received oral therapy, while ESTABLISH-2 patients received IV therapy with an optional switch to oral. The primary endpoint was early clinical response (≥20% reduction in lesion area compared to baseline at 48‐72 h after start of study drug). Investigator-assessed clinical response at the posttherapy evaluation (PTE; 7-14 days posttherapy) was a key secondary endpoint. Response rates to therapy were compared between tedizolid and linezolid with and without the presence of specified measures of disease severity at screening.

    Results: Among the 1333 patients in the pooled intent-to-treat population, there was no difference in the specified measures of disease severity between patients randomized to tedizolid (n = 664) and linezolid (n = 669). Early clinical response rates were similar between the tedizolid and linezolid treatment groups across all evaluated severity subgroups (Figure 1).  Similar response rates between the two antibacterials were also maintained for investigator-assessed clinical response at PTE across all evaluated measures of severity.

    Conclusion: In the pooled data for these two phase 3 trials for ABSSSI, 6 days of TZD was consistently non-inferior to 10 days of LZD, regardless of the measure of disease severity used.


    Figure 1. Early Clinical Response by Severity Measures

    Taylor Sandison1, Carisa De Anda1, Edward Fang1, Anita Das2 and Philippe Prokocimer1, (1)Cubist, San Diego, CA, (2)InClin, San Mateo, CA


    T. Sandison, Cubist: Employee, Salary

    C. De Anda, Cubit: Employee and Shareholder, Salary

    E. Fang, Trius/Cubist: Employee, Salary

    A. Das, Cubist: Consultant, Consulting fee
    Cempra: Consultant, Consulting fee
    Cerexa: Consultant, Consulting fee
    Nabriva: Consultant, Consulting fee
    Paratek: Consultant, Consulting fee
    Trius: Consultant, Consulting fee
    Achaogen: Consultant, Consulting fee
    Durata: Consultant, Consulting fee

    P. Prokocimer, Cubist: Employee and Shareholder, Salary

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek